Novartis strengthens executive committee further
Novartis this week announced changes to its senior leadership team to support the implementation of its strategic priorities. These changes include the appointment of Shannon Klinger in the elevated and expanded role of chief ethics, risk, and compliance officer, effective April 1.
Related articles
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
OpinionThe AI audit burden: Why ‘Explainable AI’ is the key
AI decisions are only defensible when the reasoning behind them is visible, traceable, and auditable. Explainable AI delivers that visibility, turning black-box outputs into documented logic that compliance officers can stand behind when regulators, auditors, or stakeholders demand answers.
-
ArticleFrench court calls out alleged deceptive net zero claims by TotalEnergies
Regulators in Europe are focused on punishing energy firms that make deceptive claims on net zero targets, as TotalEnergies recently discovered.